Dr. Boris Naraev Joins TGH Cancer Institute
Dr. Boris Naraev is a prominent figure specializing in the treatment and research of gastrointestinal, neuroendocrine, and endocrine cancers. His extensive knowledge and commitment aim to improve patient outcomes significantly.
Impact on Cancer Care
Recently, Dr. Naraev became part of the Tampa General Hospital (TGH) Cancer Institute, joining as a medical oncologist. His role will not only bolster clinical care but also advance research in treating challenging cancers. Dr. Eduardo M. Sotomayor, vice president and executive director of the TGH Cancer Institute, expressed high hopes regarding Dr. Naraev's contributions.
Dr. Sotomayor stated, "The strength of my enthusiasm for Dr. Naraev is based on his prestigious academic credentials and his clinical research accomplishments to date in the highly specialized area of neuroendocrine and endocrine cancers, where he is a recognized national leader." This sentiment reflects the confidence of TGH leaders in Dr. Naraev's abilities.
Experience and Expertise
Before joining TGH, Dr. Naraev worked at the Anderson Family Cancer Institute at the Jupiter Medical Center. There, he led the Gastrointestinal, Neuroendocrine, and Rare Cancers Program. His experience extends to the Banner MD Anderson Cancer Center where he played an integral role in establishing one of the largest neuroendocrine cancer programs in the southwestern United States.
Moreover, Dr. Naraev served as an adjunct assistant professor with the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, located in Houston. His education includes a Doctor of Medicine degree, earned Summa Cum Laude in 1994, along with a Doctor of Philosophy in Medical Sciences in 2001 from Orenburg State Medical Academy.
Collaboration at TGH
Dr. Noman Ashraf, another medical oncologist at TGH, collaborates closely with Dr. Naraev in managing patients with solid tumors. Ashraf mentioned, "Dr. Naraev's accomplishments in clinical care, research, and education make him an incredibly valuable asset to our team. I'm confident in his ability to provide our patients cutting-edge treatment and access to novel clinical trials." Together, they strive to enhance the quality of care provided at the TGH Cancer Institute.
Understanding Endocrine and Neuroendocrine Tumors
Endocrine tumors originate from hormone-producing cells located in various glands, such as the thyroid, adrenal, parathyroid, and pituitary. In contrast, neuroendocrine tumors are rare and derive from neuroendocrine cells, which share characteristics of both nerve and hormone-producing cells.
Driving Innovations in Cancer Treatment
Dr. Richard Tuli, deputy director of the TGH Cancer Institute, praised Dr. Naraev's powerful influence since his arrival. He brought innovative and potentially groundbreaking clinical trials to the institute, addressing the needs of patients with neuroendocrine, endocrine, and gastrointestinal cancers. Tuli expressed gratitude in having a nationally recognized expert on radiopharmaceutical therapy as part of their team.
Vision for the Future
For Dr. Naraev, joining the TGH Cancer Institute was a dream come true. He expressed admiration for the institute's commitment and approach to patient care. "To be part of one of the nation's best medical centers is something I've always dreamed of," he shared. His passion and dedication to translating this enthusiasm for innovative patient care are driving forces in his work.
Dr. Abraham Schwarzberg, who oversees oncology at TGH, views Dr. Naraev's inclusion as a key element in enhancing the hospital’s reputation as a leading health care center. Schwarzberg declared, "We are thrilled to have a renowned educator, researcher, and exceptional physician join us in our efforts to deliver world-class care to all of our patients."
TGH Cancer Institute's Recognition
The TGH Cancer Institute stands out as one of the few Florida cancer centers integrated with academic medicine, securing its spot as one of the top 50 cancer centers nationwide, as reported by U.S. News & World Report. The institute is renown for offering comprehensive care that leverages advanced diagnostic tools and collaborative treatment approaches, aiming for the best patient outcomes.
TGH Cancer Institute’s recognition stems from its commitment to healing, using cutting-edge therapies and maintaining an environment of collaborative medical practice. It prioritizes meeting high health care quality standards and providing patients with the best resources for their treatment.
Frequently Asked Questions
1. What is Dr. Naraev’s role at TGH Cancer Institute?
Dr. Boris Naraev serves as a medical oncologist specializing in gastrointestinal, neuroendocrine, and endocrine cancers.
2. Where did Dr. Naraev work before joining TGH?
Dr. Naraev previously worked at the Anderson Family Cancer Institute and Banner MD Anderson Cancer Center.
3. What types of cancers does Dr. Naraev focus on?
He specializes in treating gastrointestinal, neuroendocrine, and endocrine tumors.
4. What does the TGH Cancer Institute offer?
The institute provides comprehensive cancer care, advanced diagnostic imaging, and access to cutting-edge clinical trials.
5. How is the TGH Cancer Institute recognized nationally?
The institute ranks among the top 50 cancer centers in the United States according to U.S. News & World Report.
